Arrowhead Pharmaceuticals (ARWR) Amortizatization of Intangibles (2011 - 2016)
Arrowhead Pharmaceuticals' (ARWR) quarterly Amortizatization of Intangibles came in at $30556.0 in Q3 2016, down 81.53% YoY from $165410.0 in Q4 2015, and up 39.61% on a QoQ basis from $21886.0 in Q2 2016.
Powered by 
Analysis
Arrowhead Pharmaceuticals (ARWR) Amortizatization of Intangibles (2011 - 2016) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 6 years of Amortizatization of Intangibles data on file, last reported at $30556.0 in Q3 2016.
- Quarterly Amortizatization of Intangibles fell 81.53% year-over-year to $30556.0 in Q3 2016, while the trailing twelve-month figure through Sep 2016 was $231902.0 (down 79.12% YoY) and the FY2016 annual result came in at $231902.0, down 79.12% from the prior year.
- Amortizatization of Intangibles rose to $30556.0 in Q3 2016, from $21886.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $377596.0 in Q3 2014 to a low of -$26918.0 in Q2 2012.
- A 5-year average of $119490.8 and a median of $46065.0 in 2013 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2013 — Amortizatization of Intangibles surged 4872.55% — and 2016, when it tumbled 92.09%.
- Tracing ARWR's Amortizatization of Intangibles over 5 years: stood at $572.0 in 2012, then surged by 4872.55% to $28443.0 in 2013, then soared by 1122.46% to $347703.0 in 2014, then slumped by 68.82% to $108403.0 in 2015, then plunged by 71.81% to $30556.0 in 2016.
- The last three Amortizatization of Intangibles figures came in at $30556.0 (Q3 2016), $21886.0 (Q2 2016), and $71057.0 (Q1 2016), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Arrowhead Pharmaceuticals | 12.40 Bn | 10.80 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2016 | 30,556.00 |
| Jun 30, 2016 | 21,886.00 |
| Mar 31, 2016 | 71,057.00 |
| Dec 31, 2015 | 108,403.00 |
| Sep 30, 2015 | 165,410.00 |
| Jun 30, 2015 | 276,750.00 |
| Mar 31, 2015 | 320,661.00 |
| Dec 31, 2014 | 347,703.00 |
| Sep 30, 2014 | 377,596.00 |
| Jun 30, 2014 | 146,978.00 |
| Mar 31, 2014 | 240,870.00 |
| Dec 31, 2013 | 28,443.00 |
| Sep 30, 2013 | 46,065.00 |
| Jun 30, 2013 | 45,410.00 |
| Mar 31, 2013 | 36,359.00 |
| Dec 31, 2012 | 572.00 |
| Sep 30, 2012 | 30,023.00 |
| Jun 30, 2012 | -26,918.00 |
| Mar 31, 2012 | 2,502.00 |
| Dec 31, 2011 | 3,783.00 |